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OBJECTIVES: To study the cost related to the management of type 2 diabetes mel-
litus (T2DM) in public health care by standard approach as a means to assist in the 
evaluation of health services in Brazil. METHODS: A small municipality was con-
sidered for this study, with less than 50,000 habitants, it is representative of 81% of 
the state’s municipalities and 89% of Brazil’s. The data sources used were obtained 
from the Municipal Health Office and public data systems online. Direct medical 
costs were selected according to standard care recommended by the Ministry of 
Health and Brazilian Associations of Cardiology and Diabetes, and lately divided 
into three categories of analysis: Health professional salary, Procedures and tests 
costs, and Medication costs, both for Primary Health Care (PHC) and Medium/High 
Complexity Care (MHCC). RESULTS: In 2011, the total expense in a year for a user 
with T2DM was U$ 491.04, regarding the individual without complication, attended 
in PHC. After developing chronic complications (either microvascular or macro-
vascular), the patient continues to receive PHC, but also needs the attention of 
specialists, therefore costs for specific treatments in MHCC services were added to 
the PHC costs. The sum ranged from U$ 732.86 for nephropathy to U$ 3182.59 for 
Acute Myocardial Infarction. In evaluation of each category of analysis, the invest-
ment made by the National Health System in the management of T2DM showed 
uneven distribution, where a subcategory of Health professionals salary, the PHC’s 
doctors salary, represented an important share of spending in exchange of others 
categories. CONCLUSIONS: The standard cost method is presented as an alterna-
tive that offers greater convenience and flexibility in the determination of costs 
to assist health managers in decision-making, considering the shortcomings of 
Brazilian’s information system.
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OBJECTIVES: To measure the cost associated with an acute coronary event through 
a retrospective cohort study of patients in Saludcoop EPS, Cafesalud Cruz Blanca 
EPS and EPS during the first six months of 2013 in Colombia. METHODS: Through 
a retrospective analysis of 2943 patients with acute coronary event were identified 
with ICD-10-associated acute coronary syndrome, which were reported by each 
of the EPS to the Ministry of Health and Social Protection of Colombia. The first 
part of the study involved the characterization of the population by age group, 
gender, region and comorbidities. The second part includes an analysis of the 
use of hospital services and average stay in the hospital. In the third part the 
analysis included the average cost of interventions such as angioplasty, heart 
surgery and thrombolysis during the first six months after the acute coronary 
event were included. RESULTS: The male population has a higher incidence of 
acute coronary event at a younger age than that of the female population. The 
male population of the department of Antioquia recorded the most interventions 
received. The average cost per patient with acute coronary event during the first 
month was 14,381,501 Colombian Pesos and 2,493,801 Colombian Pesos per patient 
during the sixth month. CONCLUSIONS: the first month represented the highest 
cost for acute coronary event with an average of 13,382,501 COP, which is 53.35% 
of the total cost per event.
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OBJECTIVES: To assess the impact of clinical pharmacist intervention (CPI) on pre-
scribing habit and cost saving throughout 12 months duration for patients receiving 
some and the same medications include (Human Albumin 20% 50ml, Meropenem 
500 mg and Ciprofloxacin 200 mg), this was via a comparison made between the 
NO-CPI (observation only) and Direct-CPI phases, in term of the number of vials 
dispensed monthly. METHODS: It is an observational cohort study and it is divided 
into two phases; Phase-I: to evaluate prescribing habit of the prescribers throughout 
two months duration (30 days with NO-CPI and 30 days with Direct-CPI) for patient 
using Human Albumin. While phase-II: to assess the impact of Direct-CPI versus 
NO-CPI on cost saving throughout 10 months duration ( 5 months with NO-CPI and 5 
months with Direct-CPI). The number of dispensed vials for each item was recorded 
by CP. RESULTS: The study findings in phase-I showed that Direct-CPI lead to statis-
tically significant (P < 0.0001) improvement of prescribing for human albumin 20%, 
especially in cases with albumin level > 3 g/dl, it was 36% with NO-CPI versus 1.6% 
with Direct-CPI, and in cases with albumin level < 2 g/dl, and it was 6% with NO-CPI 
versus 42% with Direct-CPI. In phase II, during 5-months of Direct-CPI compared 
with the same duration of No-CPI, there was a remarkable monthly cost saving, and 
it was 54% for Human Albumin, 55% for Meropenem and 59% for Ciprofloxacin. This 
resulted in total cost saving for all three items equal to 123,735 US Dollar during 
the five months of Direct-CPI. CONCLUSIONS: Direct-CPI can significantly improve 
prescribing habit and lead to a substantial cost saving.
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ment hospitals from charging patients in situations where that total admission 
cost exceeds the case rate. These policies aim to provide financial protection to 
patients while promoting efficiency in hospitals. There are concerns that tertiary 
government hospitals might end losing money as they managed mostly compli-
cated cases. To assess this possibility, the cost of admission for pneumonia cases 
admitted in the internal medicine ward of a tertiary government hospital in the 
Philippines was estimated. The proportion of pneumonia admissions where costs 
did not exceed case rates was also determined. METHODS: A random sample of 
admissions for pneumonia for two severity classes (moderate-risk and high-risk) 
from January 1 to June 30 2013 was obtained. Costs considered were diagnostic 
tests, medications, mechanical ventilator use and overhead costs. Due to the lack 
of billing reports, costs of diagnostics tests and medications were computed via 
tallies from chart review. Overhead costs were estimated using WHO-CHOICE 2007 
values for the Philippines. RESULTS: A sample of 112 moderate-risk and 42 high-risk 
pneumonia cases were included in the study. The mean total costs were US$ 564.55 
for moderate-risk and US$ 727.01 for high-risk. 29.5% of moderate-risk cases had a 
total cost less than the case rate of US$ 333 and 68.2% of high-risk cases had a total 
cost less than the case rate of US$ 711.11. Considering costs and reimbursements 
for all admissions, the hospital will lose US$ 25,895.11 due to moderate-risk and 
US$ 2,121.77 due to high-risk admissions. CONCLUSIONS: Estimated mean total 
costs exceed the case rates of PhilHealth for pneumonia. The case rates may not 
be adequate to cover the total costs of admission in a government tertiary hospital 
in the Philippines.
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OBJECTIVES: Compare direct costs of medical care before and after heart failure (HF) 
hospitalization in a Medicare population. METHODS: A 5% (n= 3,493,434) national 
sample of Medicare beneficiaries for the years 2006-2012 was used to identify indi-
viduals with at least 65 years of age at the date of hospital admission for HF, enrolled 
in Medicare Parts A and B and not enrolled in a Medicare Advantage plan. Total costs 
were summed (in constant 2012 dollars) for all services utilized by the hospitalized 
beneficiary every month during observation the period. The total costs for each 
month before, after and during the month of HF hospitalization were plotted. Costs 
of an HF episode were calculated as difference in total reimbursements in the six 
months during and after the month of hospitalization and the six months preced-
ing the event. The incremental analysis allows individuals to serve as their own 
controls. RESULTS: There were 63,678 eligible episodes of HF hospitalizations. In the 
six months prior to the month of hospitalization total costs were $14,212 and in the 
six months following discharge, total costs were $24,645. The cost (total costs for all 
services utilized) during the month of hospitalization was $14,967. CONCLUSIONS: 
The cost of care in the six months following a HF hospital discharge was more 
than $10,000 higher than those in 6 months prior to the hospitalization. Avoiding 
hospitalizations for patients with HF would be desirable not only because they are 
costly but also because the cost of care remains higher for at least six months fol-
lowing the hospitalization.
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OBJECTIVES: To measure the intervention costs of the Pharmacists’ Pneumonia 
Prevention Project (PPPP), a community-based pneumonia education and vaccina-
tion program administered to older Philadelphians in 2014. METHODS: PPPP involved 
a pharmacist informational presentation, a live skit, small-group breakouts, and 
optional vaccination. Attendees could consent to participate in program assess-
ments if they were aged 50+, cognitively intact, and English speaking. Recruitment 
and program coordination were completed through partnerships with churches and 
senior centers. The total cost from a health system perspective was the sum of time 
costs (pharmacy, community health workers; CHWs for travel, training, supervision 
and planning), supplies (vaccine, medical, and office supplies), actor and site fees. 
Time requirements for each program date were recorded using a staff log. Wages 
were applied to time using U.S. Bureau of Labor Statistics rates plus fringe ben-
efits applicable to each partnering institution. Volunteer pharmacy students were 
assigned zero time costs. RESULTS: Among 276 individuals who attended PPPP, 203 
consented to program assessments and were mostly female (74.9%), black (80.4%), 
and the mean age was 74. PPPP was offered on 8 dates at 4 community locations. 
Mean staff requirements for each date were 5.5 students, 3.6 pharmacists, and 2 CHW. 
The total program cost was $32,513 (per-attendee cost = $118). Time costs associated 
with planning ($11,927), program delivery ($8,659), and non-volunteer travel ($2,257) 
represented 70.3% of the total cost. Time and expenses for vaccination ($7,861) also 
contributed substantially to PPPP costs (24.2%), while actors’ fees ($1,750) represented 
5.4%. Excluding vaccination costs and actor costs would yield per-attendee costs of 
$89.32 and $82.98, respectively. CONCLUSIONS: Resources requirements for PPPP are 
high, but will be further evaluated in terms of outcomes achieved (knowledge gains, 
vaccination rate). Costs could be offset by reimbursement for vaccination, omitting 
this component, and/or using a video skit rather than live actors.
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OBJECTIVES: The aim of this study was to measure cancer-related direct expen-
ditures and its determinants, from the third-party payer perspective, for patients 
newly diagnosed and treated by the National Health System (SUS) from 2000 
to 2003. METHODS: We used data from national administrative registries of all 
patients treated by the SUS. We restricted our sample to patients newly diagnosed 
between the years 2000 and 2003 with the most prevalent cancers in Brazil (breast, 
cervix, prostate, lung, colorectal and stomach). Data included expenditures related 
to chemotherapy and radiotherapy and in-patient care. A generalized linear model 
with a gamma distribution was used to estimate the determinants of healthcare 
expenditures. Regressions were performed for the whole sample and then sepa-
rately by cancer type. RESULTS: A total 180,283 patients were diagnosed with cancer 
between 2000 and 2003: 38.6% breast, 19.1% cervix, 15.4% prostate, 11.3% lung, 10.8% 
colorectal and 4.9% stomach cancer. Average monthly expenditures were 315$ and 
the average follow-up of 18 months. The highest average monthly expenditure was 
observed for lung cancer (649$) followed by stomach cancer (382$). High discrep-
ancies were observed between states, from 210$ (Maranhão) to 471$ (Roraima). 
All covariates were significantly related to expenditures. Monthly expenditures 
decreased with follow-up time and increased with death and presence of metas-
tases. Expenditures were lower among women and decreased continuously with 
patient’s age, with the lowest expenditures observed among patients older than 80. 
As compared to cancer in situ, lower expenditures were observed for stage I; by con-
trast, expenditures were much higher at stage III and IV. Covariates behaved simi-
larly across cancer types, except for the stage of disease. CONCLUSIONS: Average 
monthly expenditures for cancer treatment in Brazil are relatively low as compared 
e.g. to estimates for the US. The strong discrepancy between States raises serious 
concerns about equity and quality.
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OBJECTIVES: NPS MedicineWise Australia developed and implemented a multi-
faceted academic detailing program to improve general medical practitioner pre-
scribing of antipsychotic therapy. A significant component of this program focused 
on the appropriate use of medicines for older people with dementia. Evidence has 
demonstrated that older adults in community and residential aged care facilities 
are prescribed antipsychotics for the management of their dementia symptoms 
despite lack of evidence of benefit. This study is an economic evaluation of the NPS 
MedicineWise educational program in terms of reduced falls and stroke incidence 
due to reduction in antipsychotic prescribing including olanzapine, quetiapine 
and risperidone METHODS: A cost-benefit analysis was performed to evalu-
ate the costs and benefits of preventing hospitalisations due to strokes and falls 
as a result of reduced antipsychotic prescribing due to the program. A decision 
tree model was constructed using TreeAge Pro 2014. Data sources were from our 
clinical audit, general practitioner survey and interrupted time series analyses of 
administrative data from the Australian Pharmaceutical Benefits Scheme (PBS). A 
meta-analysis was conducted to provide outcome data on the reduction of antipsy-
chotics. Probabilistic sensitivity analysis was performed to address any parameter 
uncertainty using Monte Carlo simulation. RESULTS: Following implementation of 
the NPS MedicineWise intervention, a reduction in prescription of atypical antip-
sychotics among older adults was observed in the PBS. Modelling of this reduction 
translated into a reduction in the incidence of both stroke and fall hospitalisations 
among this cohort resulting in costs avoided for Government. CONCLUSIONS: This 
is a comprehensive economic analysis conducted in Australia to have utilised PBS 
data and large scale evaluation results to examine interventions focussing on the 
appropriate use of medicines in older adults. The results will be used to further 
inform future public health interventions aimed at managing the health outcomes 
of this vulnerable and growing population.
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OBJECTIVES: Our clinical trial compared two behavioral psychosocial interventions 
tailored for children with ADHD-inattentive type (ADHD-I) which varied in intensity 
and outcomes. We evaluated cost-effectiveness of the Child Life and Attention Skills 
(CLAS) program, which has parent, teacher and child sessions, and the parent-
focused treatment (PFT), which includes only parent sessions, both compared with 
traditional community treatment (TAU). METHODS: We used our recent clinical trial 
for data on resources used and treatment outcomes. Our CEA outcome was cost 
per ADHD case avoided as measured by the Child Symptom Inventory. Costs for 
CLAS and PFT included clinician, parent, and teacher time, supplies, and childcare. 
TAU costs included only supplies. Salaries were from Bureau of Labor Statistics in 
2011 USD. Savings were calculated from reductions in parent time spent on home-
work and lost leisure and work time based on surveys taken before and 7 months 
post-treatment. Sensitivity analyses assessed the impact of altering CLAS struc-
ture, including having personnel of varying educational background lead group 
sessions. RESULTS: Total cost per patient for CLAS, PFT, and TAU were $1,655.04, 
$795.03, and -$9.37, respectively. CLAS, the costliest, was also more effective than 
PFT and TAU; 39, 34, and 11 cases avoided. The incremental cost-effectiveness ratio 
(ICER) was $4,368.63 per disordered case avoided for CLAS compared to TAU. PFT 
compared to TAU was lower at $2,564.56. The ICER of CLAS compared to PFT was 
$12,684.49. Reducing the number and length of group meetings resulted in an ICER of 
$3,333.05 for CLAS compared to TAU. CONCLUSIONS: PFT is the more cost-effective 
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OBJECTIVES: Unreported adverse drug reactions (ADRs) are of big concerns to 
medication safety in the outpatient setting. To improve ADR reporting, we used a 
Telephonic Interactive Voice Response System (IVRS) that interoperates with EHR 
(electronic health records) and pharmacist to assess and detect possibility of ADRs 
symptoms related to outpatient medications. In this study we estimated the cost 
of possible ADR symptoms reporting using IVRS. METHODS: 5872 eligible patients 
from a large health system in greater Boston were identified. To be eligible they had 
to be an adult patient seen in primary care at one of 8 participating clinics, received 
a new prescription for an oral medication to treat hypertension, diabetes, depres-
sion, or insomnia. Using IVRS, we contacted patients 4-6 weeks and again at 4-6 
months after the date the drug was prescribed, to document any patient-reported 
symptoms related to ADRs. Costs per patient contacted, respondent patient, and 
patient reporting a possible ADR were estimated. Direct health care costs and cost 
of patient’s time for the intervention were included in the analysis. Costs of health 
care resources and personnel were derived from the hospital financial accounting 
system. RESULTS: Of the total patients contacted (5872), 10.3% responded, 7.3% 
were transferred to pharmacist and 5.2% reported symptoms to the IVRS. The total 
cost per patient contacted was estimated at $12.29. Pharmacist’s salary represented 
66.7% of the cost per patient contacted. The cost per respondent patient, cost per 
call transferred to pharmacist and cost of symptoms reported per patient were 
estimated to be $118.51, $167.85 and $235.86 respectively. CONCLUSIONS: Systems 
like IVRS with real-time linkages to a clinical pharmacist, may facilitate early detec-
tion of possible ADRs related to prescription medications and do so with relatively 
little cost per patient. Earlier detection of adverse drug reactions may help reduce 
the costs related to primary care visits and hospitalizations.
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